Atara Biotherapeutics 将来の成長

Future 基準チェック /56

Atara Biotherapeuticsは、51.1%と32.7%でそれぞれ年率51.1%で利益と収益が成長すると予測される一方、EPSはgrowで51.5%年率。

主要情報

51.1%

収益成長率

51.54%

EPS成長率

Biotechs 収益成長	25.4%
収益成長率	32.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	18 May 2026

今後の成長に関する最新情報

Recent updates

分析記事 • Feb 16

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong...

Seeking Alpha • Nov 30

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Summary Atara Biotherapeutics is on the precipice of being behind an FDA approval for a novel cell therapy. However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Read the full article on Seeking Alpha

分析記事 • Oct 09

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...

分析記事 • Aug 13

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

分析記事 • May 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

分析記事 • May 01

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

分析記事 • Mar 07

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Unfortunately for some shareholders, the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price has dived 27% in the...

Seeking Alpha • Jan 21

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Summary Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO. ATRA estimates that available cash along a newly announced $15M equity line of credit are sufficient to fund operations through approval, but the risk of further cash raise is real. Read the full article on Seeking Alpha

分析記事 • Jan 16

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

分析記事 • Jan 07

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders have had their patience rewarded with a 34% share price jump...

分析記事 • Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...

分析記事 • Jul 21

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

Seeking Alpha • Jul 03

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise. Read the full article on Seeking Alpha

分析記事 • May 14

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Shareholders in Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) may be thrilled to learn that the analysts have just...

分析記事 • May 11

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

To the annoyance of some shareholders, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares are down a considerable 26...

Seeking Alpha • Feb 06

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Summary Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway. Read the full article on Seeking Alpha

業績と収益の成長予測

NasdaqGS:ATRA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	42	9	N/A	4	4
12/31/2027	51	21	N/A	16	4
12/31/2026	1	-16	N/A	-12	2
3/31/2026	23	-9	-26	-26	N/A
12/31/2025	121	33	-51	-51	N/A
9/30/2025	152	23	-70	-70	N/A
6/30/2025	189	6	-64	-64	N/A
3/31/2025	200	-16	-67	-67	N/A
12/31/2024	129	-85	-69	-69	N/A
9/30/2024	100	-133	-95	-95	N/A
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	N/A	-236	N/A
9/30/2019	N/A	-292	N/A	-234	N/A
6/30/2019	N/A	-279	N/A	-230	N/A
3/31/2019	N/A	-256	N/A	-215	N/A
12/31/2018	N/A	-231	N/A	-180	N/A
9/30/2018	N/A	-186	N/A	-147	N/A
6/30/2018	N/A	-159	N/A	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATRAは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。

収益対市場: ATRA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ATRA今後 3 年以内に収益を上げることが予想されます。

収益対市場: ATRAの収益 ( 32.7% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ATRAの収益 ( 32.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATRAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/21 13:32
終値	2026/05/21 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Atara Biotherapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。16

アナリスト	機関
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Michael King	Citizens JMP Securities, LLC

Atara Biotherapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 15%

Price target decreased by 32% to US$8.67

Consensus EPS estimates increase by 71%

Price target increased by 11% to US$17.00

Forecast to breakeven in 2025

Price target increased by 16% to US$15.33

Recent updates

President notifies of intention to sell stock

New major risk - Financial position

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics Provides Update on Tabelecleucel Regulatory Pathway

Atara Biotherapeutics, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 09, 2026

Pomerantz Law Firm Announces Filing Of Class Action Against Atara Biotherapeutics Inc. And Certain Officers

New major risk - Shareholder dilution

Full year 2025 earnings: EPS misses analyst expectations

Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel

Investor sentiment improves as stock rises 36%

Atara Biotherapeutics, Inc. Announces Pierre Fabre Pharmaceuticals Submits A Request to the FDA for Type A Meeting

Consensus EPS estimates increase by 15%

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Price target decreased by 32% to US$8.67

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo™ (Tabelecleucel)

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Atara Biotherapeutics, Inc. Announces Reduction in Its Workforce

Investor sentiment deteriorates as stock falls 19%

Pierre Fabre Pharmaceuticals Inc. Announces Transfer from Atara Biotherapeutics Inc. of the Biologics License Application (Bla) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 23%

Atara Biotherapeutics Announces Changes to Its Board of Directors

Consensus EPS estimates increase by 71%

Investor sentiment improves as stock rises 19%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Price target increased by 11% to US$17.00

Atara Biotherapeutics, Inc. Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®?) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Share price stability

New major risk - Shareholder dilution

Pierre Fabre Pharmaceuticals Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc

Atara Biotherapeutics, Inc. Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Insider selling

Atara Biotherapeutics, Inc. Appoints James Huang and Nachi Subramanian to Board of Directors, Effective from May 14, 2025

Forecast to breakeven in 2025

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $16.004932 million.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO™? (Tabelecleucel)

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Price target increased by 16% to US$15.33

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2025

Consensus revenue estimates decrease by 96%, EPS upgraded

Price target decreased by 7.5% to US$12.25

No longer forecast to breakeven

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Consensus EPS estimates fall by 365%

Atara Biotherapeutics, Inc. Provides Update on Clinical Programs Related to Ebvallo™? (Tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

New major risk - Share price stability

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024